More flexible FDABiogen’s pricey recently somehow controversial approved Alzheimer’s drug sparked a bit of criticism from some folks within FDA as they didn’t believe the therapeutic benefits of the drug justified the approval, few resigned but the temporary commissioner Janet woodcock who many blame for the approval of the drug seems to have backing of senate members from both parties, there are also many patients advocacy groups including oncology groups who have supported her in the last few months. Even president Biden has defended her in her decision making efforts. Now Lilly is filing for accelerated approval for their Alzheimer’s drug. As many hardliners within FDA have left we could see more flexible FDA which is open to approvals of drugs for unmet conditions NASH and late stage cancers included.